• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY:NNVC)

1.125 +0.005 (+0.45%)
Streaming Delayed Price Updated: 1:46 PM EDT, Sep 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 187,602
Open 1.110
Bid (Size) 1.120 (800)
Ask (Size) 1.130 (9,900)
Prev. Close 1.120
Today's Range 1.100 - 1.130
52wk Range 0.8500 - 2.230
Shares Outstanding 15,641,611
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Registers Phase II Ebola Trial for NV-387 Oral Gummies
Today 9:55 EDT
Via Investor Brand Network
Topics Intellectual Property
News headline image
Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo
Today 8:30 EDT
From NanoViricides
Via ACCESS Newswire

Performance

YTD
-7.0%
-7.0%
1 Month
-19.6%
-19.6%
3 Month
-21.3%
-21.3%
6 Month
+14.8%
+14.8%
1 Year
-21.9%
-21.9%

More News

Read More
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Advances NV-387 Measles Treatment Program Toward Phase II Trial
August 31, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
August 31, 2026
From NanoViricides
Via ACCESS Newswire
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Expects Phase II Ebola Trial of NV-387 Oral Gummies to Begin Soon in DRC
August 18, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon
August 18, 2026
From NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Receives Regulatory Approval for Phase II Ebola Trial of NV-387 Oral Gummies
August 10, 2026
Via Investor Brand Network
Topics Death Intellectual Property
News headline image
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak
August 10, 2026
From NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Awaits Regulatory Decision on Ebola Trial for NV-387 Oral Gummies
July 28, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial
July 28, 2026
From NanoViricides
Via ACCESS Newswire
NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Announces Approximately $3.8 Million Registered Direct Offering
July 24, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering
July 24, 2026
From NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Seeks Approval to Launch Phase II Ebola Trial in DRC
July 22, 2026
Via Investor Brand Network
Topics Death Intellectual Property
News headline image
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola
July 22, 2026
From NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Receives Ethics Approval for Phase II Ebola Trial in DRC
July 13, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo
July 13, 2026
From NanoViricides
Via ACCESS Newswire
MissionIRNewsBreaks – NanoViricides (NYSE American: NNVC) Coverage Initiated With Outperform Rating, $6 Price Target
July 08, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily
July 08, 2026
From NanoViricides
Via ACCESS Newswire
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Advances NV-387 Toward Phase II Trial for Bundibugyo Ebola in DRC
July 06, 2026
Via Investor Brand Network
Topics Death Intellectual Property
News headline image
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo
July 06, 2026
From NanoViricides
Via ACCESS Newswire
News headline image
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher
June 29, 2026
From NanoViricides
Via ACCESS Newswire
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Ships NV-387 Drug Supply to DRC for Phase II MPox Trial
June 22, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
June 22, 2026
From NanoViricides
Via ACCESS Newswire
NetworkNewsBreaks – NanoViricides (NYSE American: NNVC) Receives DRC Approval to Advance Proposed Phase II Ebola Trial
June 15, 2026
Via Investor Brand Network
Topics Intellectual Property
News headline image
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo
June 15, 2026
Via ACCESS Newswire

Frequently Asked Questions

Is NanoViricides, Inc. Common Stock publicly traded?
Yes, NanoViricides, Inc. Common Stock is publicly traded.
What exchange does NanoViricides, Inc. Common Stock trade on?
NanoViricides, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for NanoViricides, Inc. Common Stock?
The ticker symbol for NanoViricides, Inc. Common Stock is NNVC on the New York Stock Exchange
What is the current price of NanoViricides, Inc. Common Stock?
The current price of NanoViricides, Inc. Common Stock is 1.125
When was NanoViricides, Inc. Common Stock last traded?
The last trade of NanoViricides, Inc. Common Stock was at 09/08/26 01:46 PM ET
What is the market capitalization of NanoViricides, Inc. Common Stock?
The market capitalization of NanoViricides, Inc. Common Stock is 17.60M
How many shares of NanoViricides, Inc. Common Stock are outstanding?
NanoViricides, Inc. Common Stock has 18M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap